EHA 2023 Highlights Podcast

In this episode (12.15), Medicom’s correspondent covers 6 presentations from the annual meeting of the European Hematology Association (EHA 2023), held from 8-11 June, in Frankfurt, Germany.

The topics discussed are:

1. COMMANDS trial: Paradigm shift in LR-MDS-associated anaemia
   Luspatercept was superior to epoetin alfa in treating anaemia in erythropoiesis-stimulating agent (ESA)-naïve patients with transfusion-dependent lower-risk myelodysplastic syndromes. The safety profile of luspatercept was manageable and predictable.
2. CARTITUDE-4: cilta-cel meets expectations in lenalidomide-refractory MM
   Cilta-cel was superior to standard-of-care in patients with lenalidomide-refractory multiple myeloma (MM), results from the phase 3 CARTITUDE-4 trial showed. According to the authors, cilta-cel has the potential to become the new standard-of-care for patients with lenalidomide-refractory MM after a first relapse
3. Good results for zandelisib in relapsed/refractory indolent B-cell NHL
   Zandelisib displayed a high response rate in heavily pre-treated patients with relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma, including patients with poor prognoses. The safety analysis revealed a low rate of grade ≥ 3 adverse events of special interest.
4. Promising data for zitomenib in relapsed/refractory NPM1-mutated AML
   Ziftomenib displayed encouraging clinical activity in a heavily pre-treated population of patients with relapsed/refractory NPM1-mutated acute myeloid leukaemia. The agent was well-tolerated and the lack of predicted adverse drug-drug interactions suggests that ziftomenib could be explored in combination with other agents.
5. REVIVE: rusfertide meets primary endpoint in PV
   Compared to placebo, rusfertide was associated with improved response rates in patients with polycythaemia vera (PV). The drug met all the efficacy endpoints, was well-tolerated, and is currently being investigated in the phase 3 VERIFY trial.
6. Investigational agent performs well in PNH
   The MASP-3 inhibitor OMS906 appeared safe and displayed encouraging signs of efficacy in the interim analysis of a phase 1b trial involving patients with treatment-naïve paroxysmal nocturnal haemoglobinuria (PNH). Several trials are underway to further evaluate this agent in the PNH population.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 28 June 202327 June 2024